MGLL and Parkinson disease: Pharmacological inhibition of MAGL leads to reduction of neuroinflammatory responses in a manner associated with 2-AG increase and with AA, IL1β, IL6 or TNFα decrease in various animal models, such as LPS-induced neuroinflammation [106], MPTP-induced Parkinson, and genetic models of Alzheimer and SLA [62,82,106]